AKRO Share Price Performance
US$50.46
25.72 (103.96%)
Price US$50.46
Share PriceUS$50.46
AKRO Community Narratives
There are no narratives available yet.
Recent AKRO News & Updates
No updates
Akero Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.38
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 3.3%
Akero Therapeutics, Inc. Competitors
About AKRO
- Founded
- 2017
- Employees
- 69
- CEO
- WebsiteView website
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
U.S. Market Performance
- 7 Days: 2.3%
- 3 Months: 12.9%
- 1 Year: 20.2%
- Year to Date: 8.3%
The Consumer Staples sector gained 3.2% while the market remained flat over the last week. As for the longer term, the market has risen 20% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading